To the Editor:

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare dermatopathic hematological malignancy derived from plasmacytoid dendritic cell (pDC) precursors. It co-exists with other myeloid malignancies in >20% of cases, and especially frequently with chronic myelomonocytic leukemia (CMML) [1]. Given emerging data for shared clonal origin [2, 3] and supportive clonal pDCs characterizing the CMML microenvironment [4], these diseases might share common biology and therapeutic vulnerabilities. However, their detailed genomic landscape, clonal relationship, and distinctive pathogenesis remain unclear.

A 73-year-old male presented with widespread purpuric lesions over trunk and limbs (Supplementary Fig. 1). Ten years earlier he was diagnosed with low-risk CMML-0, managed throughout by active surveillance. Skin biopsy confirmed BPDCN, with infiltration by moderately proliferative (Ki67 50%) blasts expressing the classic diagnostic triad of CD4, CD56, and CD123 [1], alongside BCL2, CD10, CD33, TdT, and CD99. Blood count revealed a stable monocytosis (1.4 × 10^9/L) and neutropenia (1.4 × 10^9/L), but a normal platelet count. Bone marrow (BM) was heavily infiltrated by CMML, with hypercellular, dysplastic myelomonocytic precursors but no blast/promonocyte excess. Flow cytometry of BM revealed 26% CD64+CD14+ monocytes, 1% CD34+ myeloblasts, and 1% neoplastic pDCs (CD4+CD56+CD123+HLA-DR+NG2+), indicating low-level BPDCN involvement. Karyotype was normal. Non-intensive treatment with azacitidine was commenced. After three cycles skin lesions remained unchanged. BM showed regression of CMML but now extensive (>70%) involvement by BPDCN. Azacitidine was discontinued and he was managed with supportive care. Shortly after he developed central visual loss with choroidal infiltrates, indicating central nervous system...
infiltration. He declined lumbar puncture and died 9 months after BPDCN diagnosis.

Samples were collected from BM, skin and buccal swab at BPDCN presentation, and from BM following azacitidine. Six samples were prepared for analysis: CD34+ hematopoietic stem/progenitor cells (“HSPC-BM-1”) and CD4+CD56+CD123+ BPDCN cells (“BPDCN-BM-1”) (from presentation BM by flow sorting); whole skin biopsy from a presenting BPDCN lesion (“BPDCN-SK-1”); sorted BM BPDCN cells post-azacitidine (“BPDCN-BM-2”); CD4+CD56+CD123+); and buccal swab as germline control. All samples underwent whole exome sequencing (WES) on the IonTorrent™ platform (Fig. 1A; Supplementary Methods; Supplementary Table 1; Supplementary Fig. 2).

In total 249 somatic variants (involving 241 genes) were identified across the five sequenced exomes, 97 involving coding regions or splice sites with predicted translational consequence (Supplementary Table 2). A TET2 p.Glu1010Ter nonsense somatic mutation was present in all samples, with mean VAF 50.8% (range 49.8–52.3%). Five somatic mutations were common to all samples, indicating a shared founding clone arising within the HSPC compartment and propagated across both diseases. In addition to the TET2 mutation was a pathogenic splice site mutation in ZRSR2, a 5’UTR variant of the E3-ubiquitin ligase TRIM4, and passenger (noncoding/synonymous) mutations in MYO7B and THSD7B.

Downstream, the CMML and BPDCN samples displayed markedly different mutation profiles and evolutionary paths, indicating early clonal divergence (Fig. 1B–D; Supplementary Fig. 3) and disease-specific secondary driver lesions (Fig. 2). CMML-BM-1 harbored cancer-associated mutations including MPL p.Tyr591Asp, CHD4 p.Arg877Gln, and MAP4K3 p.Met220Val; the latter altering the kinase domain of a protein reportedly dysregulated by TET2 silencing [5]. All CMML-BM-1 mutations were also detectable (at lower VAF) in HSPCs, indicating malignant evolution from the TET2/ZRSR2-mutated founding clone within the CD34+ compartment. None were detected in any BPDCN specimen.

By contrast, many more genetic lesions were identified in the BPDCN samples. SciClone resolved nine distinct
mutation clusters (Fig. 2). Two large clusters (C2; C3) included mutations displaying high (~40–60%) VAF in all three BPDCN samples, but absent from the HSPC-BM-1 or CMML-BM-1 samples, suggesting a “secondary” BPDCN-initiating event likely outside the CD34 compartment and after pDC precursor egress from BM. These included a hotspot mutation in the putative oncogene MED12 (p.Gly44Ser), and mutations involving the transcription

![Mutation oncoprint](image-url)
factor GLIS3 and Rac GTPase regulator DOCK1. SciClone segregated mutation clusters distinct to either BPDCN-SKIN-1 (C5) or BPDCN-BM-1 (C4; C8), indicating subclonal divergence between the cutaneous and BM diseases following recirculation back to BM (Fig. 1C, D). Only C4 was detected in (and dominated) BPDCN-BM-2, highlighting the subclone responsible for BPDCN progression through azacitidine; this included COSMIC-annotated pathogenic mutations involving CDK18 (p.Glu275Lys) and EBF3 (p.Arg129Cys). An NRAS p.Tyr64Asn mutation was identified in BPDCN-BM-1 only, indicating presence in a clone outcompeted and/or suppressed by azacitidine.

HSPCs contained no high-confidence CNVs. By contrast, all BPDCN samples displayed a significant CNV burden, indicating relative genomic instability. These all harbored a ~5 Mb deletion at chromosome 12p13.31 encompassing 72 genes, including ETV6 and others with documented roles in DC migration/function (Supplementary Fig. 4). Accordingly, BM cytogenetics post-azacitidine confirmed add(12)(p11.2) and ETV6 loss by FISH in 56/100 cells (Supplementary Fig. 5). Other CNVs were private to individual samples, indicating later subclonal events (Supplementary Fig. 4). These included several regions of copy gain across chr12 (BPDCN-BM-1); trisomies 2 and 7 (BPDCN-SK-1); chr20 gain and deletions involving the TNF receptor-associated TRAF7 and MTOR-associated protein MLST8 (chr16p13.3) (BPDCN-BM-2).

A shared clonal origin of CMML and BPDCN has been proposed previously. Targeted sequencing of a similar patient found TET2 and SRSF2 mutations in both BM MNCs and contemporaneous skin biopsy, indicating these as shared early events. JAK2 was mutated exclusively in BM as a presumed CMML-specific subclonal event [2]. Another case reported WES on unsorted BM MNCs from CMML presentation and later at BPDCN, again demonstrating shared ancestry (including a TET2 mutation) whilst implicating biallelic RB1 loss in BPDCN transformation [3]. This implied BPDCN transforming directly from CMML, through acquisition of additional genetic lesions.

Ours is the first study to directly partition CMML and BPDCN from the same compartment, and to sequence (at exome level) sorted subpopulations from different sites and timepoints. We too demonstrate shared initiation, but with remarkably distinct subsequent evolutionary paths in a complex genomic landscape. Again, TET2 loss-of-function was a shared ancestral event, mirroring its known recurrence in both diseases [6, 7]. For the first time we collated 20 cases of BPDCN co-existing with CMML (or its precursor clonal hematopoietic states), including several previously unpublished (Supplementary Table 3). Remarkably, TET2 was mutated in 13/13 (100%) of sequenced cases, implying ubiquity in this context and significantly higher frequency versus reported series of unselected BPDCN (p = 0.0002; Fisher’s exact test; Supplementary Fig. 6). The divergent phylogenetic paths in our patient epitomize the promiscuous malignant potential of TET2 dysfunction, and the influence of cellular context and secondary lesions in modulating resultant malignant phenotype. This reconciles with observations in murine models, in which Tet2 loss biased HPSCs toward production of both macrophages and DCs, from distinct multipotent progenitor populations, establishing discrete foundations for both diseases [8].

No BPDCN-exclusive mutations were detected in the CD34+ compartment. Thus, although rooted in a preleukemic HSPC, BPDCN transformation occurred via a “secondary” initiation event in a more committed cell, in keeping with its typically CD34-negative immunophenotype [1]. A core set of shared mutations across all BPDCN samples implicates the minor BPDCN-BM-1 population as part of the malignant clone, rather than a benign clonal pDC expansion (a documented feature in CMML-BM [4]). Relative disease proportions in BM and skin suggest extramedullary initiation with subclonal recirculation back to BM. Subsequently one BPDCN subclone outcompeted the other, synchronous with regression of the CMML (also outcompeted, or eradicated by azacitidine).

The most prominent BPDCN-specific lesion was ETV6 loss, conclusively lacking from CMML cells so precluding detection on initial BM cytogenetics. ETV6 encodes an ETS family transcription factor that is a key regulator of HSPC function and tumor suppressor. ETV6 disruption was recently linked to BPDCN [9, 10], with 12p karyotypic abnormalities commonly seen [1]. We also identified MED12 p.Gly44Ser in BPDCN for the first time, as a novel candidate “secondary” driver mutation. This hotspot mutation occurs frequently (~70–80%) in uterine leiomyoma and breast fibroepithelial tumors (plus their malignant equivalents), 5–10% of chronic lymphocytic leukemias, and sporadically in other cancers [11]. Intriguingly, the highest MED12 expression in hematopoiesis is reportedly in pDCs (Supplementary Fig. 7), and it is prominently induced upon ex vivo DC activation [12], indicating functional importance in DCs.

MED12 encodes a kinase module of the transcriptional coactivator Mediator complex, conveying signals from chromatin-bound transcription factors at enhancers through recruitment of RNAPII to promoters. Oncogenic Gly44 mutations impair MED12’s ability to activate CDK8 and CDK19, dysregulating key transcriptional networks [13]. They are tumorigenic in murine models, mediating widespread genomic instability [14]. Notably, TP53, CDKN2A and RB1 inactivation, prominent inducers of genomic instability and common in BPDCN, were absent in our patient. MED12 mutations might phenocopy these and represent an alternative route to genomic instability: a fundamental intermediate event in BPDCN pathogenesis. Interestingly MED12 is X-linked, and not confirmed to escape X-inactivation; if Gly44 substitutions confer tumorigenic gain-of-function as has been proposed [14].
this could further contribute to BPDCN’s striking (3:1) male preponderance.

We investigated whether MED12 mutations are recurrent in BPDCN. Few suitable existing BPDCN sequencing datasets were identified. We reviewed four published [3, 15] and two unpublished BPDCN-BM exomes, plus eight BM samples sequenced by a 300-gene panel [7]. We also sequenced MED12 exons 1–2 in 15 archived BM and 9 skin biopsies, validating the mutation in our index patient but finding no others in this limited cohort (Supplementary Fig. 8). Nonetheless, our study highlights this well-described oncogenic mutation as a novel potential BPDCN downstream of the apparently ubiquitous TET2-mutant foundation for this important clinical association.

Acknowledgements We thank Florence Pethick, Stephen Knight, and Katelyn Gilmour (ThermoFisher) for their support with the AmpliSeq Exome sequencing. This work was supported by the Oglesby Charitable Trust. DHW is additionally supported by a Blood Cancer UK Clinician Scientist Fellowship [grant number 15030]. HMB is additionally supported by a donation from the Pickering family. TS is supported by Cancer Research UK grant number C5759/A20971. DPW received salary support from Cancer Research UK grant number C5759/A20971.

Compliance with ethical standards

Conflict of interest The authors declare no competing interests.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Khoury JD. Blastic plasmacytoid dendritic cell neoplasm. Curr Hematol Malig Rep. 2018;13:477–83.
2. Brunetti L, Battista VD, Venanzi A, Schiavoni G, Martelli MP, Ascani S, et al. Blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia: a shared clonal origin. Leukemia. 2017;31:1238–40.
3. Patnaik MM, Lasho T, Howard M, Finke C, Ketterling RL, Al-Kali A, et al. Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms. Blood Cancer J. 2018;8:82.
4. Lucas N, Duchmann M, Rameau P, Noël F, Michea P, Saada V, et al. Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia. Leukemia. 2019;33:2466–80.
5. Berggren DM, Folkvaljon Y, Engvall M, Sundberg J, Lambe M, Antunovic P, et al. Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register. Br J Haematol. 2018;181:614–27.
6. Coltro G, Mangaonkar AA, Lasho TL, Finke CM, Pophali P, Carr R, et al. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMMML)—a study of 1084 patients. Leukemia. 2020;34:1407–21.
7. Beird HC, Khan M, Wang F, Alfayez M, Cai T, Zhao L, et al. Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood Cancer J. 2019;9:99.
8. Ostrander EL, Kramer AC, Mallaney C, Celik H, Koh WK, Fairchild J, et al. Divergent effects of Dnmt3a and Tet2 mutations on hematopoietic progenitor cell fitness. Stem Cell Rep. 2020;14:551–60.
9. Gao NA, Wang X-X, Sun J-R, Yu W-Z, Guo N-J. Blastic plasmacytoid dendritic cell neoplasm with leukemic manifestation and ETV6 gene rearrangement: a case report. Exp Ther Med. 2015;9:1109–12.
10. Tang Z, Li Y, Wang W, Yin CC, Tang G, Aung PP, et al. Genomic aberrations involving 12p/ETV6 are highly prevalent in blastic plasmacytoid dendritic cell neoplasms and might represent early clonal events. Leuk Res. 2018;73:86–94.
11. Zhang S, O’Regan R, Xu W. The emerging role of mediator complex subunit 12 in tumorigenesis and response to chemotherapeutics. Cancer. 2020;126:939–48.
12. Costa V, Righelli D, Russo F, Berardinis PD, Angelini C, D’Apice L. Distinct antigen delivery systems induce dendritic cells’ divergent transcriptional response: new insights from a comparative and reproducible computational analysis. Int J Mol Sci. 2017;18:494.
13. Park MJ, Shen H, Spaeth JM, Tolvanen JH, Failor C, Knudtzon JF, et al. Oncogenic exon 2 mutations in Mediator subunit MED12 disrupt allosteric activation of cyclin C-CDK8/19. J Biol Chem. 2018;293:4870–82.
14. Mittal P, Shin Y-h, Yatsenko SA, Castro CA, Surti U, Rajkovic A. Med12 gain-of-function mutation causes leiomyosarcoma and genomic instability. J Clin Investig. 2015;125:3280–4.
15. Meneses J, Acquadro F, Wiseman M, Gómez-López G, Salgado RN, Talavera-Cañas JG, et al. Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. Leukemia. 2014;28:823–9.